Skip to content

Journal of Addictive Diseases

ISSN 1055-0887

4 papers in the library · 47 citations · publishing 1999-2023

Papers

Hallucinogen persisting perception disorder: A literature review and three case reports

Journal of Addictive Diseases October 2, 2018 Valentin Yurievich Skryabin, М.а. Винникова, A. Yu. Nenastieva et al. 27 citations

Hallucinogen persisting perception disorder (HPPD) is described through diagnostic criteria, clinical presentations, types, and treatment approaches. Three case reports illustrate different types: a 23-year-old with prior cannabis use developed HPPD type I after taking psilocybin mushrooms with alcohol and hash, with symptoms recurring after cannabis but not alcohol, and reducing within a year. Two other cases of HPPD type II occurred after ecstasy use, which is not typically considered a hallucinogen; the condition was stressful and frightening, and treatment with tofisopam, lamotrigine, and sertraline smoothed but did not eliminate visual impairments. Scientific sources suggest HPPD may affect more than 50% of hallucinogen users and is often underdiagnosed.

LSD Use and Flashbacks in Alcoholic Patients

Journal of Addictive Diseases April 5, 1999 Wayne Bemis Batzer, Thomas F. Ditzler, Christopher R. Brown 12 citations

Lysergic Acid Diethylamide (LSD) is a hallucinogenic drug that gained attention in the 1960s and early 1970s, producing perceptual disturbances that sometimes persisted long after the drug left the system, known as "flashbacks." These flashbacks may have contributed to the drug's decline in recreational use. This report describes histories of LSD use among alcoholism treatment facility inpatients and details flashback characteristics and associated subjective distress. Findings indicate a statistically significant relationship between the number of doses taken and the incidence of flashbacks.

Hallucinogenic mushroom misuse reported to Texas poison centers

Journal of Addictive Diseases May 18, 2020 Mathias B. Forrester 6 citations

Between 2000 and 2018, Texas poison centers managed 486 cases of hallucinogenic mushroom misuse, primarily involving psilocybin. Most patients were male (85%), with an average age of about 21 years. Ingestion alone accounted for 91% of exposures, and 72% occurred at the patient's own residence. The majority of patients (71%) were already at or en route to a healthcare facility when the poison center was contacted, while 22% were referred to a facility. The most common clinical effects were neurological (72%), cardiovascular (25%), and gastrointestinal (23%). Misuse predominantly involved adolescents and young adults and was typically managed in healthcare settings.

Prevalence of psilocybin use in vaping and associated factors: a study among amphetamine-type stimulants (ATS) use disorder in Malaysia

Journal of Addictive Diseases August 4, 2023 Ruzmayuddin Mamat, Rusdi Abd Rashid, Baharudin Ibrahim et al. 2 citations

Psilocybin use in vaping is increasing among amphetamine-type stimulant users and across broader populations, yet knowledge about its long-term health effects remains limited. The authors call for further research to highlight harmful effects and the potential risks of psilocybin vaping, especially among younger people.